A Phase 3 interventional study of MCI-186 and Placebo of MCI-186 in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients who met severity classification III.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
This study's enrollment of 25 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Browse Amyotrophic Lateral Sclerosis studies →Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MCI-186
Drug: Placebo of MCI-186
Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Also known as: Edaravone, Radicut
Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
No primary endpoint was used, because various exploratory analyses were performed. 0=worst; 48=best
Time frame: baseline and 24 weeks
Death or a Specified State of Disease Progression
No primary endpoint was used, because various exploratory analyses were performed. Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.
Time frame: 24 weeks
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
No primary endpoint was used, because various exploratory analyses were performed.
Time frame: baseline and 24 weeks
Percentage of Participants With Adverse Events
No primary endpoint was used, because various exploratory analyses were performed.
Time frame: 24 weeks
Percentage of Participants With Adverse Drug Reactions
No primary endpoint was used, because various exploratory analyses were performed.
Time frame: 24 weeks
The Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients
No primary endpoint was used, because various exploratory analyses were performed.
Time frame: 24 weeks
Percentage of Participants With Abnormal Changes in Sensory Examinations
No primary endpoint was used, because various exploratory analyses were performed.
Time frame: 24 weeks
| Milestone | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Started | 13 | 12 |
| Completed | 9 | 12 |
| Not completed | 4 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Patient's convenience | 1 | 0 |
No primary endpoint was used, because various exploratory analyses were performed. 0=worst; 48=best
| units on a scale | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks | -6.52 ± 1.78 | -6 ± 1.83 |
No primary endpoint was used, because various exploratory analyses were performed. Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.
| events | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| death | 1 | 0 |
| disability of independent ambulation | 4 | 2 |
| loss of upper arm function | 1 | 2 |
| tracheotomy | 0 | 0 |
| use of respirator | 0 | 0 |
| use of tube feeding | 1 | 0 |
No primary endpoint was used, because various exploratory analyses were performed.
| percentage of FVC | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks | -18.75 ± 4.58 | -15.69 ± 4.58 |
No primary endpoint was used, because various exploratory analyses were performed.
| percentage of participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Percentage of Participants With Adverse Events | 92.3 | 100 |
No primary endpoint was used, because various exploratory analyses were performed.
| percentage of participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Percentage of Participants With Adverse Drug Reactions | 23.1 | 8.3 |
No primary endpoint was used, because various exploratory analyses were performed.
| percentage of participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| White blood cell count (WBC) | 23.1 | 8.3 |
| Other laboratory tests except for WBC | 0 | 0 |
No primary endpoint was used, because various exploratory analyses were performed.
| percentage of participants | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| Numbness | 0 | 0 |
| Staggering | 10 | 0 |
| Vibratory sensation | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MCI-186 | — | 3/13 (23.1%) | 12/13 (92.3%) |
| Placebo of MCI-186 | — | 2/12 (16.7%) | 12/12 (100%) |
| Event | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| DysphagiaGastrointestinal disorders | 2/13 | 0/12 |
| Musculoskeletal disorderMusculoskeletal and connective tissue disorders | 1/13 | 1/12 |
| Pelvic venous thrombosisVascular disorders | 0/13 | 1/12 |
| Gait disturbanceGeneral disorders | 1/13 | 0/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/13 | 0/12 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/13 | 0/12 |
| Event | MCI-186 | Placebo of MCI-186 |
|---|---|---|
| DyscheziaGastrointestinal disorders | 0/13 | 3/12 |
| StomatitisGastrointestinal disorders | 0/13 | 3/12 |
| DiarrhoeaGastrointestinal disorders | 3/13 | 1/12 |
| Gait disturbanceGeneral disorders | 3/13 | 1/12 |
| HeadacheNervous system disorders | 3/13 | 2/12 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 3/13 | 1/12 |
| NasopharyngitisInfections and infestations | 2/13 | 2/12 |
| Joint sprainInjury, poisoning and procedural complications | 0/13 | 2/12 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/13 | 2/12 |
| ConstipationGastrointestinal disorders | 2/13 | 0/12 |
| Age, Categorical(Participants) | MCI-186 | Placebo of MCI-186 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 10 | 21 |
| >=65 years | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | MCI-186 | Placebo of MCI-186 | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 7 | 6 | 13 |
No study locations are listed for this record.
Ran from Dec 2006 to primary completion in Jul 2008, 19 months.
Results were first posted in Dec 2017, 9 years 4 months after primary completion.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone
Amyotrophic Lateral Sclerosis →